Implementing Wearable Technologies to Measure Clinical Outcomes in Multiple Sclerosis:

A Scoping Review

Authors: Sarah Alexander¹, Guy Peryer², Emma Gray³, Frederik Barkhof¹,4,5,6, Jeremy Chataway¹,5

1. Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, UK
2. School of Health Sciences, Edith Cavell Building, University of East Anglia, UK
3. Clinical Trials Unit, UK Multiple Sclerosis Society, MS National Centre (MSNC), UK
4. Centre for Medical Image Computing (CMIC), Department of Medical Physics and Biomedical Engineering, University College London, UK
5. National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre, UK
6. Department of Radiology and Nuclear Medicine, VU University Medical Centre, Amsterdam, NL

Acknowledgments
Supported by the MS Society and the Expert Consortium for Progression in MS Clinical Trials: Outcome Measures Working Group

Disclosures
SA does not have any disclosures.

GP has received consultancy sums from the MS Society and the Eastern Academic Health Science Network, and paid employment from the NIHR East of England Applied Research Collaboration.

EG does not have any disclosures.

FB is a board member for Neurology, Brain, Radiology, MSJ, and a section editor for Neuroradiology. He has also received personal fees from Springer, Bayer, Biogen, IXICO Ltd, GeNeuro and Roche as well as grants from Novartis, TEVA, Merck, Biogen, IMI-EU, GE Healthcare, UK MS Society, Dutch Foundation MS Research, NWO, and NIHR, outside the submitted work.

In the last 3 years, JC has received support from the Efficacy and Evaluation (EME) Programme, a Medical Research Council (MRC) and National Institute for Health Research (NIHR) partnership and the Health Technology Assessment (HTA) Programme (NIHR), the UK MS Society, the US National MS Society and the Rosetrees Trust. He has been a local principal investigator for a trial in MS funded by the Canadian MS society. A local principal investigator for commercial trials funded by: Actelion, Biogen Idec, Novartis and Roche; has received an investigator grant from Novartis; and has taken part in advisory boards/consultancy for Azadyne, Biogen, Celgene, MedDay, Merck and Roche.

Wearable technology refers to any sensor worn on the person, making continuous and remote monitoring available to many people with chronic disease, including multiple sclerosis (MS). Daily monitoring seems an ideal solution either as an outcome measure or as an adjunct to support rater-based monitoring in both clinical and research settings. There has been an increase in solutions that are available yet there is little consensus on the most appropriate solution to use in either MS research or clinical practice. We completed a scoping review (using the PRISMA-ScR guidelines) to summarise the wearable solutions available in MS in order to identify those approaches that could potentially be utilised in clinical trials, by evaluating: scalability, cost, patient adaptability and accuracy. We identified 35 unique products that
measure gait, cognition, upper limb function, activity, mood and fatigue with most of these solutions being phone applications.

Key Words: Multiple Sclerosis, Wearable Technology, mHealth, Biosensors, remote sensing technology, mobile applications

Introduction:
Assessment of new treatments in multiple sclerosis (MS) studies necessitates effective, reliable, and validated outcome measures. Most clinical MS outcome measures are rater-dependant and are applied episodically. Clinical trials in MS require sensitive outcome measures, that can detect small changes in disability or functional improvement on a frequent basis, which can then reliably reflect long term changes.

With the advances in technology over the last few decades, it is now possible to explore methods of accurate, sensitive and objective continuous remote monitoring. Wearable technology, otherwise often referred to as biosensors or smart sensors, are mobile technology solutions that can be worn by the person and often include passive or active tracking capabilities which can be used to assess health and well-being. Common examples of these devices include the FitBit® activity band and smartphone applications like MapMyRun®. Advancements in wearable technology and phone applications (“apps”) enable continuous patient-based monitoring and provide feedback on daily life. The results of daily monitoring using wearable technology could be used either as an outcome measure or as an adjunct to support rater-based assessments. There has been an increase in solutions that are available for those who are diagnosed with chronic illness, especially in regards to neurological disease. Yet, there is little consensus on the most appropriate solution to use in either MS research or clinical practice.

Studies, have shown that patients, caregivers, and healthcare professionals find value in using such devices especially when they are less-invasive in day-to-day situations and provide real-time feedback. Currently, there are no published randomised control trials (RCTs) that have utilised wearable technology in PwMS, however there are several RCTs currently on-going that utilise wearable technology, for example, the MD3001 (SPI2) trial.

The advantages and disadvantages of wearable technology are summarised in the table below.
Table 1: Potential advantages and disadvantages of wearable technology in trials

| Advantages                              | Disadvantages                             |
|-----------------------------------------|-------------------------------------------|
| Continuous or frequent monitoring       | Cost of device                             |
| Remote monitoring ability               | Secure data storage                        |
| Less invasive                           | Local skin irritation                      |
| Decreased travel burden for participants| Troubleshooting device                     |
| Feedback to the participant             | Charging and battery life of devices       |
| Ease of use                             | Software upgrade incompatibility           |

The rationale for conducting this scoping review was to understand each solution and their utility in multiple sclerosis. This review was commissioned by the Outcome Measures working party as part of the Expert Consortium on Progression in MS Clinical Trials, which is a UK MS Society initiative. We reviewed wearable technology solutions with a particular interest in their potential to detect changes in function for PwMS in a more reliable and accurate manner, and their suitability for use in a UK wide multi-centre platform trial.

Objective:
To identify all validated wearable solutions for PwMS and determine suitability for use in a UK wide multi-centre platform trial by considering the following factors; reproducibility in MS populations, feasibility (including cost), patient adaptability and prior use in an RCT.

Methods:
We used a scoping review approach which aims to map the key concepts underpinning a research area especially where an area has not been reviewed comprehensively before (PRISMA-ScR).\(^{10}\)

Our search strategy utilized subject heading searches: ‘Multiple Sclerosis’ and ‘wearable electronic devices’, as well as keywords ‘wearable technology’, and ‘electronic devices’. The literature search was conducted using MEDLINE (via PubMed) and Embase (via OVID) databases. This search included articles published from database inception to 30 May 2019. Additional searches looked at authors that have frequently published with different devices as well as forward and backward citation tracking of included papers. The scoping review followed the PRISMA-ScR guidelines.\(^{11}\)

When examining suitability of a wearable device for use in a UK wide multi-centre platform trial, we considered several factors: reproducibility (defined as the number of studies examining the solution in
MS), feasibility (including cost), patient adaptability and prior use in an RCT. The results of this is shown in Tables 2 and 3.

**Study Eligibility Criteria**

The inclusion criteria were defined as: (1) primary research studies that used wearable technology in a cohort of PwMS of all ages (adult or paediatric), (2) studies from any geographical location, (3) reported in the English language. Exclusion criteria were defined as: (1) wearable solutions intended for another health condition, (2) non-wearable solutions, (3) non-primary research such as narrative reviews, (4) abstracts that did not have full-text available.

After screening titles and abstracts, duplicates were removed and the full-text of each paper was assessed for eligibility according to the criteria stated above.

**Data Extraction**

The data to be extracted for each article were determined in consultation with the second author (GP) and a data extraction form was created. Descriptive characteristics were extracted where available for: (1) wearable device, (2) cohort, (3) type of study, (4) purpose, (5) functional area of assessment and (6) outcome.

Developers of the wearable technology were separated into the following categories:

- Health-care related agency: Hospitals, clinics, or government organisations directly related to health care
- Pharmaceutical company: entities with commercial purposes to research, develop, market or distribute drugs in the context of healthcare
- Educational organisation: any educational organisations such as universities, colleges, libraries or schools not directly related to health care
- Small and medium enterprises: start-ups, software developing companies, or any other private organization that identified themselves as an enterprise and not individuals

**Results:**

The searches yielded 1,880 potentially relevant articles. Removing duplicates and applying the eligibility criteria resulted in a total of 35 unique MS wearable technology solutions, which included 3 unique
solutions that were yielded from conferences and scientific meetings. Figure 1 describes the PRISMA flow diagram.
Figure 1. PRISMA Flow Diagram 12

1. Records identified through database searching (n = 1,880)
2. Additional records identified through other sources (n = 3)
3. Records after duplicates removed (n = 1,115)
4. Title/abstract screened (n = 1,115)
5. Excluded after screening (n = 949)
6. Full-text articles assessed for eligibility (n = 166)
7. Full-text articles excluded (n = 129)
   (Wearable technology in another health condition, not wearable technology, not in English language, narrative reviews, no data on completion)
8. Studies included in qualitative synthesis (n = 37)
9. Unique Solutions Identified (n = 35)
The list of the included wearable technology solutions and the frequency with which they appeared in validated studies is shown in Table 2. A majority of the solutions that were used in studies in PwMS were applications (apps), accelerometers and activity monitors. The older studies predominantly focused on measuring activity, walking or gait since activity monitors, accelerometers and gyroscopes were the most readily available and advanced technology at the time. This result is not unexpected because the nature of MS disease progression would require sensors focused on assessments based on activity and function, both easily derived from accelerometers. Included are four unique app solutions for cognition, which were all created more recently, as apps are becoming an easier wearable technology to develop and deploy. There were a handful of wearables that focused on fatigue, mood, quality of life (QoL) and self-management. At the time of review, all wearables identified had only been used in observational or interventional studies.

Table 2. Unique devices and prevalence of appearance

A summary of the general characteristics of the unique wearable technology solutions found are shown in Table 3 which can be found in the appendix.
There is significant variability in the per unit cost of each product and the decision as to which wearable
to use depends largely on the study budget and outcomes of interest. Costs may vary significantly when
using a physical wearable sensor compared to a smart-device application. Aside from per unit cost, other
considerations include repair or replacement of faulty devices, annual maintenance charges, software
package costs, return of devices, charging capabilities and collection of data (postage vs remote upload).
Physical wearable sensors risk being ‘phased out’ and being replaced with newer models that have not
been tested in an MS population. Applications may alleviate this problem by sending out software
updates, which the user can download. Users could however face problems if this update exceeds the
smart-device support capability.

There does seem to be a shift towards developing more validated wearable technology solutions for MS
and focusing on health-care adoption to make sure that dissemination of the solutions is more successful
and reaches a wider population. This is seen by the increase in the number of publications related to the
subject of wearable technology in MS. Additionally, as a result of an increased number of solutions being
validated, wearable technologies are now becoming more utilised in RCTs. At the time of writing this
review, there are no published RCTs that utilises wearable technology, however we are aware of several
other RCTs that are currently being run, that employ wearable technology such as the SPI2 and TEAMS
studies.¹³,¹⁴

Whilst doing this review, we identified 10 (27%) solutions that we classed as ‘private’ solutions as they
had been created, tested, and not available to the public, as shown in table 3. This seems to have
happened for various reasons including: not having the necessary resources to further validate or improve
the solution or not having enough resources to gain regulatory approval. All of the identified solutions
that are private and unavailable were created by health-care or educational organisations. Ideally,
independent validation prior to clinical or research use seems appropriate however this may not be
feasible due to on-going costs. When comparing this to the solutions created or funded by pharmaceutical
companies, for example the FLOODLIGHT app and the MSPT, it was shown that 98% of the solutions
created by pharmaceutical companies were successfully implemented and disseminated, as they had
enough resources to manage the on-going cost and effort required to gain regulatory approval and market
the products.
Limiting factors to consider when developing wearable technology is adherence. PwMS have shown a high level of acceptance when using smart-phone applications (apps), although this may wear off as the disease progresses due to handicaps (for example decreased hand dexterity). Factors to consider when designing a solution are: convenience, placement of the wearable device, appearance of the sensor, and feedback of results to the PwMS. Patient-feedback is extremely important in keeping PwMS interested and engaged in their own health. Many solutions have opted to patient-friendly readouts whilst more complex data and parameters are available to the respective clinicians and researchers.

Another limiting factor, from a UK perspective, was the approach from regulatory bodies. Stricter guidelines determined what was seen as a medical device or classed as an observational tool. New guidelines which have recently come into effect, such as the new Evidence Standards Framework by NICE in March 2019 and the Regulation (EU) 2017/745 by the European Parliament (May 2020), will also work to create stricter guidance for patient safety, security monitoring and data security. Many solutions that are available elsewhere, have struggled to implement themselves outside of research in the United Kingdom due to these guidelines.

Limitations
Although we used a detailed process to search and document the currently validated solutions in MS, there were several limitations. The nature of this scoping report was web-search based and thus relied on university subscription to journals to access the papers, although only 5/1115 titles screened could not be accessed in this way. The inclusion of only English language papers may also be considered a limitation.

Conclusion
In the coming years, we can expect to see more sensitive and comprehensive measures being developed, with the idea of using wearable solutions perhaps as the gold standard to measure outcome measures in studies and clinical practice. However, at present, guidelines on what wearable technology should be used in clinical practice and research are absent and this is an area that will require considerable attention and stringency.

 Whilst doing the review we came across many unvalidated solutions available for PwMS across a range of outcome measures, most of them being phone or iPad solutions. We classed a solution as ‘unvalidated’ if there was an inability to demonstrate test-retest reliability and/or failure to demonstrate difference
between healthy controls and PwMS. In comparison the validated solutions are rather limited, but are most advanced particularly in measurements of gait (characteristics) and balance. These solutions often provide the greatest accuracy and acceptance rate, as gait is one of the earliest outcome measures explored in MS wearable solutions.

Also with the advances in mobile technology, more solutions are focusing on utilising common wearables such as smart phones, smart watches, and tablets, to increase accessibility and minimise costs to the user. Looking forward, there is also a change occurring from single measure solutions to multi-measure and multi-sensor solutions, such as the Floodlight Open app, which utilises multiple sensors within a smartphone to remotely measure gait, cognition and upper limb function.

As development in wearable technology in MS is still on-going, we can expect to see newer solutions focusing on other areas with technology advancements that allow for more upper body and cognitive measures. There is a dearth of validated solutions available for fatigue, mood, and pain.

The future of wearable technology in multiple sclerosis therefore looks promising with the potential to become a primary, co-primary or adjunctive monitoring tool in research and clinical practice.
References:

1. Schwid, S. R. et al. Are quantitative functional measures more sensitive to worsening MS than traditional measures? *Neurology* 55, 1901–3 (2000).
2. Goldman, M. D., Motl, R. W. & Rudick, R. A. Possible clinical outcome measures for clinical trials in patients with multiple sclerosis. *Therapeutic Advances in Neurological Disorders* 3, 229–239 (2010).
3. Malasinghe, L. P., Ramzan, N. & Dahal, K. Remote patient monitoring: a comprehensive study. *J. Ambient Intell. Humaniz. Comput.* 10, 57–76 (2019).
4. Motl, R. W., McAuley, E. & Snook, E. M. Physical activity and multiple sclerosis: A meta-analysis. *Mult. Scler.* 11, 459–463 (2005).
5. Patel, S., Park, H., Bonato, P., Chan, L. & Rodgers, M. A review of wearable sensors and systems with application in rehabilitation. *Journal of NeuroEngineering and Rehabilitation* 9, 21 (2012).
6. Nasi, G., Cucciniello, M. & Guerrazzi, C. The role of mobile technologies in health care processes: The case of cancer supportive care. *J. Med. Internet Res.* 17, (2015).
7. Apolinario-Hagen, J., Menzel, M., Hennemann, S. & Salewski, C. Acceptance of Mobile Health Apps for Disease Management Among People With Multiple Sclerosis: Web-Based Survey Study. *JMIR Form. Res.* 2, e11977 (2018).
8. Marrie, R. A. et al. Use of eHealth and mHealth technology by persons with multiple sclerosis. *Mult. Scler. Relat. Disord.* 27, 13–19 (2019).
9. Tourbah, A. et al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. *Mult. Scler.* 22, 1719–1731 (2016).
10. Tricco, A. C. et al. PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. *Annals of Internal Medicine* 169, 467–473 (2018).
11. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. & Altman, G. Preferred reporting items for systematic reviews and meta-analyses : the PRISMA statement All use subject to JSTOR Terms and Conditions REPORTING items Preferred for systematic reviews reporting meta-analyses : the PRISMA statement. 339, 332–336 (2009).
12. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. - PubMed - NCBI. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19621072. (Accessed: 5th November 2019)
13. Rimmer, J. H. et al. Rationale and design of the tele-exercise and multiple sclerosis (TEAMS) study: A comparative effectiveness trial between a clinic- and home-based telerehabilitation intervention for adults with multiple sclerosis (MS) living in the deep south. *Contemp. Clin. Trials* 71, 186–193 (2018).
14. Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) - Full Text View - ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT02936037. (Accessed: 2nd April 2020)
15. Apolinário-Hagen, J., Menzel, M., Hennemann, S. & Salewski, C. Acceptance of Mobile Health Apps for Disease Management Among People With Multiple Sclerosis: Web-Based Survey Study. *JMIR Form. Res.* 2, e11977 (2018).
16. Dash, S., Shakyawar, S. K., Sharma, M. & Kaushik, S. Big data in healthcare: management, analysis and future prospects. *J. Big Data* 6, (2019).
### Table 3: Summary of unique solutions and their general characteristics

| Wearable in Use                      | Cohort (n =) | Type of Study | Purpose | Functional area of assessment | Outcome |
|--------------------------------------|--------------|---------------|---------|-------------------------------|---------|
| BETACONNECT, myBETAapp               | > 100 MS     | Interventional| Bayer produced app to assist the BETACONNECT auto injector and to help self-manage symptoms and dose. | Injection / Self-management | Shown to be an effective patient self-management tool for disease modifying therapy alongside auto injector. |
| FitBit Flex                          | 95 MS        | Interventional| To assess continuous step count activity remotely among PwMS for 1 year and determine how average daily step count is associated with other measures of MS disability. | Lower limb | Appears to be feasible to monitor for 1 year. It showed a decrease in average daily step count correlated to worsening of standard ambulatory measures. |
| Keeogo exoskeleton                   | 29 MS        | Interventional| An exoskeleton for lower-extremity to enable PwMS to benefit from exercise and physical activity. | Lower limb | Lower extremity exoskeleton, exercise-mediated benefit to PwMS that improves unassisted gait endurance and stair climbing. |
| TEAMS (private app)                  | 10 MS        | Observational| A Tailored tele rehabilitation app: Participant-Centered Development and Usability Study | Activity level | App that allows for PwMS to follow an exercise program and showed good usability. Currently being studied in an RCT. |
| StepWatch Activity Monitor           | 64 MS        | Observational| Understanding walking activity in MS: step count, walking intensity and uninterrupted walking activity duration related to degree of disability. | Activity level | Results showed everyday walking in PwMS was not high and that PwMS rarely walk for more than six minutes uninterrupted. |
| Digi-walker SW-200 pedometer, Jawbone UP, Jawbone UP Move, Fitbit Flex and Fitbit One AND Health app, Health Mate, Moves | 45 MS | Observational | This study examined the accuracy and precision of common smartphone applications and motion sensors for measuring steps taken by MS patients while walking on a treadmill. | Activity level | Fitbit One was the best and most precise solutions for measuring steps but more research is needed before inclusion in clinical research. |
| StepWatch Activity Monitor, GT3X+ ActiGraph | 63 MS | Observational | Accuracy of StepWatch and ActiGraph accelerometers for measuring steps taken among persons with multiple sclerosis. | Activity level | Results showed that the StepWatch was a more accurate choice of accelerometer, especially in those with higher disability levels. |
| 7164 and GT3X ActiGraph              | 41 MS, 41 HC | Observational| Comparison of ActiGraph activity monitors in persons with multiple sclerosis and controls. | Activity level | There was enough discrepancy between the two models to show they are not interchangeable under free-living conditions. |
| Device                          | Sample Size  | Study Type   | Description                                                                                                                                                                                                 | Activity Level | Notes                                                                                     |
|--------------------------------|--------------|--------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------------------------------------------------------------------------------------------|
| StepWatch Step Activity Monitor (SAM) | 9 MS         | Observational | Validity of the StepWatch Step Activity Monitor: preliminary findings for use in persons with Parkinson disease and multiple sclerosis.                                      | Activity level | Results showed that the StepWatch accurately measured step count for those with MS.       |
| ActiBelt                        | 30 MS        | Observational | Creating a robust and autonomous measurement device for long-term monitoring of patient activity.                                                                                                         | Activity level | Preliminary results are promising but the algorithm needs to be modified to allow for more sensitivity |
| Private app                     | 22 MS, 17 HC | Observational | This study illustrated some of the novel approaches that smartphones provide to monitor MS patients in their natural setting.                                                                                   | Activity level | Results show the feasibility of and barriers to deploying a smartphone platform to gather passive and active data. Overall positive data and shows smartphone platform may therefore enable large-scale studies of PwMS. |
| MS TeleCoach (app)              | 75 MS        | Observational | Assess feasibility of the MS TeleCoach offering tele monitoring of fatigue, telecoaching of physical activity and energy management over a 12-week period.                                               | Activity level | Intervention was well accepted and shows use of MS TeleCoach as a self-management tool in PwMS suffering from mild disability and moderate to severe fatigue appeared to be feasible. |
| activPAL3                       | 20 MS        | Observational | Validity of the activPAL3 activity monitor in people moderately affected by Multiple Sclerosis.                                                                                                           | Activity level | Good for moderately affected PwMS - slow walking cadence produced large inaccuracies.     |
| ActiGraph Wgt3X-BT              | 80 MS        | Observational | Used to monitor activity levels in a trial to see effect of core exercise on PwMS.                                                                                                                        | Activity level | Core exercises helped PwMS increase activity levels                                       |
| Fitbit Flex, GT3X ActiGraph     | 99 MS        | Observational | Continuous daily assessment of multiple sclerosis disability using remote step count monitoring.                                                                                                           | Activity level | Evaluated in a RMS and PMS cohort and shown to support remote step count monitoring as an exploratory outcome in MS trials.                      |
| Phone app (private)             | 5 MS         | Observational | Self-management phone app for PwMS to capture data about symptoms, physical activities, mood and goals.                                                                                                   | Activity level | Created a low fidelity prototype and the high fidelity prototype is being built to be further evaluated |
| Floodlight Open                 | 76 MS, 25 HC | Observational | Testing feasibility of remote active testing and passive monitoring using smartphones over 24 weeks.                                                                                                      | Activity level | Floodlight Open showed strong correlations to the SDMT, 9HPT and 25FW.                     |
|                                |              |              | These tests included Cognition (SDMT), Upper Limb (Pinching test and Balance Cognition, Lower limb Upper limb Quality of life)                                                                                |                | Older version of the app (FLOODLIGHT) also included the MSIS-29 which had a good correlation however this |
| Tool Name                      | Participants | Study Design  | Description                                                                                                                                                                                                                                                                                                                                 | Module Remarks                                                                                       |
|-------------------------------|--------------|---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| MSPT                          | 51 MS, 49 HC | Observational | The Multiple Sclerosis Performance Test (MSPT) is an iPad-based disability assessment tool. It includes 5 performance modules: Walking Speed Test (WST), Balance Test, Manual Dexterity Test for upper limb function, Processing Speed Test to simulate the SDMT, and Low Contrast Letter Acuity Test. | Well accepted by patients and strong correlations to their respective standard neurological test. Currently being tested for use in a clinical setting. |
| MSiDMT (private)              | 40 MS        | Observational | iPad-based SDMT test, testing correlation of the iPad solution to the SDMT.                                                                                                                                                                                                                                                                  | There was a strong correlation between the MSiDMT and the SDMT and it was well accepted by PwMS.     |
| Level Test (private app)      | 29 MS        | Observational | Smart phone embedded sensors to measure various neurological functions using gamification.                                                                                                                                                                                                                                               | Measured outcomes showed moderate correlations with various clinical scales and components of neurological examination. Certain level tests discriminated MS from HC. |
| Activity monitor (private)    | 21 MS        | Observational | Examine the impact of MS disability on physical activity behaviors involving ambulation.                                                                                                                                                                                                                                               | The activity monitor showed that daily step strongly related to gait and balance measures. EDSS and MSWS scores also strongly related to daily step count. |
| MIMU (MTw, Xsens)             | 20 HC and 10 MS | Observational | Using sensors to try and detect gait characteristics whilst ascending stairs.                                                                                                                                                                                                                                                         | Detected MS specific gait patterns that would not be picked up otherwise.                           |
| x-IMU(x-io)                   | 17 MS, 23 HC | Observational | Quantifying mobility impairment in MS, with a thigh-derived inertial sensor metric to assess the sit-to-stand and stand-to-sit transitions in the Timed Up and Go task.                                                                                                                                                                           | Shown to be effective at differentiating between HC and MS                                         |
| Dynaport sensor, OPAL sensors | 14 MS        | Observational | Using sensors to quantify gait characteristics and gait deficits from prolonged daily living measurements.                                                                                                                                                                                                                               | Validated a method to quantify walking in real life in PwMS.                                       |
| Device                  | Participants | Study Type  | Description                                                                                                                                                                                                 | Lower Limb                                                                                       |
|------------------------|--------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| OPAL sensors           | 12 MS, 12 HC | Observational | Using sensors, to quantify head and pelvis movement patterns that occur in PwMS with disability and determine how these secondary gait compensations impact on gait stability. | Efficient way to screen for excessive compensatory movements and provides information that impact mobility, stride time, gait stability. Good for identifying high risk of falls. |
| Garmin forerunner 230  | 73 MS        | Observational | Evaluate the agreement between patients' and neurologists' estimates of maximum walking ability and patients' mean maximum walking ability measured in daily life using GPS smart watch. | Confirmed patient estimate of distance walked is poor and shows that remote monitoring is a good way forward. |
| BioStampRC             | 30 MS        | Observational | A machine learning approach for gait speed estimation using skin-mounted wearable sensors.                                                                                                                  | Results support the use of wearable accelerometer arrays for estimating walking speed in normal subjects and their extension to MS patient cohorts with gait impairment. |
| OPAL sensors           | 52 MS, 21 HC | Observational | Validation study of the Instrumented Push and Release Test to quantify postural responses in persons with MS.                                                                                                  | Demonstrated strong agreement and correlation between sensor based metrics and gold standard lab measurements. Several metrics were shown to be different between PwMS and HC. |
| BioStampRC, GT3X ActiGraph | 45 MS, 15 HC | Observational | Monitoring gait in multiple sclerosis with novel wearable motion sensors.                                                                                                                                 | Results showed that the BioStamp most accurate device                                           |
| G-sensor               | 105 MS, 47 HC | Observational | This study aims to verify the feasibility of using wearable accelerometers in an ambulatory environment to assess spatiotemporal parameters of gait in people with Multiple Sclerosis (PwMS), as well as the correlation of objective data with patient-reported outcomes. | Wearable accelerometers are a useful tool for assessing gait performance in PwMS in a clinical setting, especially in mild to moderate disability. |
| OPAL sensors           | 5 MS, 13 HC  | Observational | To determine whether gyroscopic corrections improve wearable sensor data prior to measuring dynamic sway in the gait of people with Multiple Sclerosis.                                                            | The visualisation of asymmetric pelvic sway in people with MS illustrates the potential to better understand their mobility impairments for reducing fall risk. |
| Study Title                          | Participants | Study Design | Main Findings                                                                 |
|------------------------------------|--------------|--------------|------------------------------------------------------------------------------|
| My eReport France (private app)    | 180 MS       | Observational | Mobile phone application for drug adverse reaction reporting by patients with RRMS in a randomised controlled trial. Self-management Study not completed and results not yet available |
| Msdialog, app                      | 76 MS        | Observational | A web- and mobile-based software application, captures data on self-administration of subcutaneous interferon β-1a, clinical outcomes, and patient-reported outcomes in patients with multiple sclerosis outside the clinic. Self-management Well accepted by users and user retention was high over 6 weeks. PwMS found it easy to use and superior to previous methods for tracking health. |
| FAMOS (private)                    | 17 MS, 9 HC  | Observational | A wireless body measurement system to study fatigue in multiple sclerosis. Fatigue Preliminary results show significant differences between fatigued PwMS and healthy controls. This provides a new approach to study fatigue in MS but needs to be validated through larger clinical trials. |
| iPad visual scale (private)        | 52 MS, 52 HC | Observational | To explore the reliability and feasibility of electronic visual analogue scales in PwMS and health individuals. Fatigue Quality of life Reliable and useful for PwMS to register fatigue, pain, anxiety and QOL. |
| Phone app (private)                | 76 MS, 19 HC | Observational | Two smartphone tests of fine finger movements to see if correlated with neurological examination. Upper limb Good correlation with 9HPT and captured richer data than traditional measures |

**Legend**

MS: Multiple Sclerosis, HC: Healthy Control, RMS: Relapsing Multiple Sclerosis, RRMS: relapsing Remitting Multiple Sclerosis, PMS: Progressive Multiple Sclerosis, PwMS: People with multiple sclerosis, RCT: Randomised controlled trial, SDMT: Single Digit Modality Test, 25FW: 25 Foot Walk, 5UTT: 5 U-Turn Test, MSIS-29: Multiple Sclerosis Impact Scale, WST: Walking Speed Test, MSWS: Multiple Sclerosis Walking Scale, QoL: Quality of Life, 9HPT: 9-Hole Peg Test, Sloan LCLA: Sloan Low Contrast Letter Acuity, GPS: Global Positioning System